[6-methylaminomethyl-3,4-dihydro-2(1H)isoquinolin-2-yl](5-chloro-1-methyl-1H-indol-2-yl)methanone | 1253660-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: [6-methylaminomethyl-3,4-dihydro-2(1H)isoquinolin-2-yl](5-chloro-1-methyl-1H-indol-2-yl)methanone
• 英文别名: (5-chloro-1-methylindol-2-yl)-[6-(methylaminomethyl)-3,4-dihydro-1H-isoquinolin-2-yl]methanone
• CAS: 1253660-14-8
• 化学式: C₂₁H₂₂ClN₃O
• 分子量: 367.878
• InChiKey: UHQGJSOAASKOPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] INDOLE-2-CARBOXAMIDE DERIVATIVE<br/>[FR] DÉRIVÉ D'INDOLE-2-CARBOXAMIDE
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010126164A1

  公开（公告）日：2010-11-04

  To provide an indole compound having a human QRFP receptor antagonistic activity and useful as a preventive or a remedy for various disorders. A compound of a formula (I) or a pharmaceutically-acceptable salt thereof is provided: [wherein, R1 represents a hydrogen atom, a halogen, a C1-6 alkyl, etc,; R2 represents a C1-6 alkyl, or a halo-C1-6 alkyl; R3 represents a hydrogen atom, a C1-6 alkyl, etc.; R4 represents a hydrogen atom, a C1-6 alkyl, a halo-C1-6 alkyl, etc.; or R3 and R4, taken together with the nitrogen atom to which they bond, form a 3- to 6-membered aliphatic nitrogen-containing hetero ring; or R3 and Y3, taken together, form -CH2-CH2-; Y1 and Y2 are both hydrogen atoms; or Y1 and Y2, taken together, form -CH2-CH2-; and Y3 represents a hydrogen atom; or Y3 and R3, taken together, form -CH2-CH2-].

  提供一种具有人类QRFP受体拮抗活性的吲哚类化合物，用作预防或治疗各种疾病的药物。提供公式（I）的化合物或其药学上可接受的盐：[其中，R1代表氢原子，卤素，C1-6烷基等; R2代表C1-6烷基或卤代C1-6烷基; R3代表氢原子，C1-6烷基等; R4代表氢原子，C1-6烷基，卤代C1-6烷基等; 或者R3和R4结合在一起与它们键合的氮原子形成3-至6-成员的脂肪族含氮杂环; 或者R3和Y3结合在一起形成-CH2- -; Y1和Y2都是氢原子; 或者Y1和Y2结合在一起形成- - -; Y3代表氢原子; 或者Y3和R3结合在一起形成- - -]。
• INDOLE-2-CARBOXAMIDE DEIVATIVE
  申请人：Haga Yuji

  公开号：US20120035155A1

  公开（公告）日：2012-02-09

  To provide an indole compound having a human QRFP receptor antagonistic activity and useful as a preventive or a remedy for various disorders. A compound of a formula (I) or a pharmaceutically-acceptable salt thereof is provided: [wherein, R 1 represents a hydrogen atom, a halogen, a C 1-6 alkyl, etc,; R 2 represents a C 1-6 alkyl, or a halo-C 1-6 alkyl; R 3 represents a hydrogen atom, a C 1-6 alkyl, etc.; R 4 represents a hydrogen atom, a C 1-6 alkyl, a halo-C 1-6 alkyl, etc.; or R 3 and R 4 , taken together with the nitrogen atom to which they bond, form a 3- to 6-membered aliphatic nitrogen-containing hetero ring; or R 3 and Y 3 , taken together, form —CH 2 —CH 2 —; Y 1 and Y 2 are both hydrogen atoms; or Y 1 and Y 2 , taken together, form —CH 2 —CH 2 —; and Y 3 represents a hydrogen atom; or Y 3 and R 3 , taken together, form —CH 2 —CH 2 —].

  提供一种具有人类QRFP受体拮抗活性并可用于预防或治疗各种疾病的吲哚类化合物。提供一种公式(I)的化合物或其药学上可接受的盐：[其中，R1代表氢原子、卤素、C1-6烷基等；R2代表C1-6烷基或卤代C1-6烷基；R3代表氢原子、C1-6烷基等；R4代表氢原子、C1-6烷基、卤代C1-6烷基等；或R3和R4共同与它们键合的氮原子形成一个3至6成员的脂肪族含氮杂环；或R3和Y3共同形成—CH2— —；Y1和Y2都是氢原子；或Y1和Y2共同形成— — —；且Y3代表氢原子；或Y3和R3共同形成— — —]。